【Product for Licensing】siRNA Therapeutics Targeting PD-L1 for HBV

The global PD-1 and PD-L1 inhibitors market is projected to grow to $206 billion by 2031, with a compound annual growth rate (CAGR) of 17.9% during the forecast period (2024-2031). This growth is driven by the increasing prevalence of cancer and heightened awareness of immunotherapies.

The global PD-1 and PD-L1 inhibitors market is a highly competitive and evolving pharmaceutical industry sector. Currently, there are over 180 companies and more than 200 drugs competing in the market. Key players include Merck, Bristol-Myers Squibb, AstraZeneca, GSK, Roche, and others. These companies are actively advancing research and development and establishing partnerships. However, high treatment costs and side effects may suppress market expansion in the competition of personalized medicine.

Compared to traditional anti-PD-L1 monoclonal antibody treatments for chronic hepatitis B, PD-L1 siRNA products targeting PD-L1 offer more precise targeting, superior efficacy, and better safety. Moreover, these products show significant synergistic effects when used in combination with other anti-HBV drugs, such as VIR-2218 or Bepirovirsen, and no viral rebound was observed throughout the study.

In summary, siRNA products targeting PD-L1 have significant market potential and competitive advantages in the field of hepatitis B treatment.

Currently, we have a PD-L1 targeting siRNA, with First-in-Class / First-in-siRNA potential, looking for licensing partners.

If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~